Genmab, Merus see HSR waiting period expire; UK's CMA has no more questions about deal
MLex Summary: Genmab and Merus saw the Hart-Scott-Rodino waiting period expire on their merger review on Nov. 12, the companies said in a US Securities and Exchange Commission filing. Merus said...To view the full article, register now.
Already a subscriber? Click here to view full article